MBX BIOSCIENCES INC (MBX) — insider trading
Health Care · NASDAQ
MBX BIOSCIENCES INC (MBX) has 24 reported SEC Form 4 insider transactions in our data, including 5 open-market sales among the most recent 24 (latest 2026-08-04).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-04 | Azoulay Salomon | Officer (Chief Medical Officer) | Open-market sale | 370 | $65.77 | $24.3K | Form 4 |
| 2026-08-03 | Hoerter Steven L. | Director, Officer (President and CEO) | Grant / award / vesting (derivative) | 331,000 | — | $0 | Form 4 |
| 2026-08-03 | Hoerter Steven L. | Director, Officer (President and CEO) | Grant / award / vesting | 71,000 | — | $0 | Form 4 |
| 2026-08-03 | Smither John W | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 130,000 | — | $0 | Form 4 |
| 2026-08-03 | Smither John W | Officer (Chief Financial Officer) | Grant / award / vesting | 28,000 | — | $0 | Form 4 |
| 2026-06-04 | Aynechi Tiba | Director | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-06-04 | Ryder Steven | Director | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-06-04 | Hoerter Steven L. | Director | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-06-04 | Stelzer Laurie | Director | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-06-04 | Heron Patrick J | Director, 10% owner | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-06-04 | Pescovitz Ora H. | Director | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-06-04 | Mathers Edward T | Director | Grant / award / vesting (derivative) | 12,500 | — | $0 | Form 4 |
| 2026-05-08 | Azoulay Salomon | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 15,003 | — | $0 | Form 4 |
| 2026-05-08 | Azoulay Salomon | Officer (Chief Medical Officer) | Option exercise / conversion (derivative) | 55,000 | — | $0 | Form 4 |
| 2026-05-08 | Azoulay Salomon | Officer (Chief Medical Officer) | Open-market sale | 15,003 | $38.30 | $574.6K | Form 4 |
| 2026-05-08 | Azoulay Salomon | Officer (Chief Medical Officer) | Option exercise / conversion | 15,003 | $16.00 | $240.0K | Form 4 |
| 2026-05-08 | Azoulay Salomon | Officer (Chief Medical Officer) | Open-market sale | 55,000 | $38.38 | $2.11M | Form 4 |
| 2026-05-08 | Azoulay Salomon | Officer (Chief Medical Officer) | Option exercise / conversion | 55,000 | $10.46 | $575.3K | Form 4 |
| 2026-05-06 | Hawryluk P. Kent | Director, Officer (President & CEO) | Open-market sale | 607 | $29.54 | $17.9K | Form 4 |
| 2026-05-06 | Azoulay Salomon | Officer (Chief Medical Officer) | Open-market sale | 231 | $29.54 | $6.8K | Form 4 |
| 2026-05-01 | Hoerter Steven L. | Director | Grant / award / vesting (derivative) | 74,249 | — | $0 | Form 4 |
| 2026-05-01 | Hoerter Steven L. | Director | Grant / award / vesting | 11,938 | — | $0 | Form 4 |
| 2025-11-22 | Hoerter Steven L. | Director | Grant / award / vesting (derivative) | 0 | — | $0 | Form 4/A |
| 2025-11-06 | Hoerter Steven L. | Director | Grant / award / vesting (derivative) | 33,751 | — | $0 | Form 4/A |
Ask the chat about MBX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: MBX BIOSCIENCES INC (MBX).
Last updated 2026-08-04 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.